In my own dumb way that is what I was trying to get at with my question,... what if the MACE events going forward are super low,....even below 5 per month,... it would cause the trial to go on a very long time?

It would have been very helpful to us shareholders if they updated at the Bio Conference the actual number of MACE to date.

But going with an optimistic event scenario of 150 events placebo and only 50 events dosed...that takes the patients in the placebo arm down to 1,050 with the dosed arm at 1,150...And then if Apabetalone is as effective as many of are thinking/hoping it could be....maybe dang near all the events are taking place in the placebo arm at this stage...a placebo arm that has fewer and fewer patients in it.

What if the event rate has slowed to just 7 per month since that 200 number?  That would mean another 7+ months to hit 250.